A randomized, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery
A study for patients who have had Cardiac surgery using study drug QPI-1002
Sponsor: Quark Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ5716
U.S. Govt. ID: NCT02610283
Contact: Christopher Depender: 212-305-3009 / cd2686@columbia.edu
Additional Study Information: Thepurposeof the study is to test whether or not QPI-1002 could be used to lessen or prevent acute kidney injury after heart surgery. Another purpose is to better understand the safety of QPI-1002.
This study is closed
Investigator
Michael Argenziano, MD, FACS
Do You Qualify?
Have you recently undergone heart surgery? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Christopher Depender
cd2686@columbia.edu
212-305-3009
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE